Collectively, our discovery of a druggable ADAM17‐sIL‐6R axis in KRAS mutant LAC represents an attractive new strategy for the development of therapies for LAC and potentially other oncogenic KRAS‐addicted cancers. Here, KRAS is linked to cancer.